Roche submits science-based targets for net zero by 2045

2024-10-11

Basel, 11 October 2024 - Roche announced today its submission of greenhouse gas (GHG) reduction targets to the Science Based Targets initiative (SBTi), underscoring its commitment to addressing climate change.

Since 2004, Roche has been implementing carbon dioxide reduction measures that have led to an absolute decrease of 67% in Scope 1 and 2 emissions.

As part of its ongoing sustainability efforts, Roche has expanded its carbon reduction strategy to include both near- and long-term targets. These targets seek to reduce GHG emissions across its operations (Scope 1 and 2) and throughout its up- and downstream value chain (Scope 3). The goal is to achieve net zero emissions across Roche’s entire value chain by 2045. The SBTi is currently validating these targets. Roche’s existing commitment remains to achieve absolute zero Scope 1 and 2 emissions by 2050.

By setting science-based targets, Roche contributes to mitigating climate change and minimising the environmental impact. Roche’s commitment to sustainability encompasses the entire value chain from research and development to manufacturing and distribution.

“For two decades, everyone at Roche has been working towards significantly reducing the company's carbon footprint. So far, we have cut our own emissions by 67%,” said Thomas Schinecker, Group CEO at Roche. “By submitting these science-based targets, we hold ourselves accountable to the highest standards and contribute to more sustainable healthcare systems.”

Roche is dedicated to continuously improving its environmental performance and fostering a sustainable future for generations to come. The company believes that sustainable value and growth can only be achieved by collaborating with stakeholders and engaging in open, constructive dialogue. By doing so, Roche generates societal value and attains sustainable economic growth.

Further information on our sustainability activities can be found here: www.roche.com/sustainability

About the Science Based Target Initiative (SBTi)
The Science Based Targets initiative (SBTi) drives ambitious climate action in the private sector by enabling organisations to set science-based emissions reduction targets. The SBTi is a partnership between Carbon Disclosure Project (CDP), the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi is the lead partner of the Business Ambition for 1.5°C campaign – an urgent call to action from a global coalition of UN agencies, business and industry leaders, mobilising companies to set net zero science-based targets in line with a 1.5°C future.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person, we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com